Saturday, December 17, 2005

Tamoxifen Ineffective In Presence Of Genetic Variation in Breast Cancer

MedIndia, December 17, 2005
Researchers at the University of Michigan and the Mayo Clinic say that the flagship breast cancer drug, tamoxifen might not be very effective in women who inherit a common genetic variation. This particular variant gene has the ability to influence the levels of a crucial enzyme that is vital to activate tamoxifen against breast cancer. An oncologist at the Mayo Clinic, found that women who carried a variant of this gene had low levels of the CYP2D6 enzyme. This in turn predisposed for a relapse of the breast cancer. CYP2D6 enzyme is responsible for the metabolization of tamoxifen and plays a crucial role in triggering off the drug's activity against the cancer cells.

0 Comments:

Post a Comment

<< Home

/* WebRing Code */